QURE
uniQure NV
NASDAQ · Healthcare · Biotechnology · NL
$23.03
−3.52%Next report
Analyst consensus
- Next report date
- Mar 1, 2027
- EPS estimate
- -$0.90
- Revenue estimate
- $7.6M
Latest reported
- Last report date
- Nov 4, 2026
- EPS actual
- -$0.88
- EPS estimate
- -$0.92
- Revenue actual
- $5.2M
- Revenue estimate
- $6.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -4.7%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $36
- PT range
- $28 – $48
- Analysts
- 3
1 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 4, 2026 | -$0.92 | -$0.88 | Beat 3.87% | $5.2M |
| Jul 29, 2026 | -$0.82 | -$1.22 | Miss -48.37% | $5.8M |
| May 5, 2026 | -$0.88 | -$0.85 | Beat 3.41% | $3.6M |
| Jul 29, 2025 | -$0.89 | -$0.69 | Beat 22.47% | $5.3M |
| May 9, 2025 | -$1.07 | -$0.82 | Beat 23.36% | $1.6M |
| Feb 27, 2025 | -$0.60 | -$1.50 | Miss -150.00% | $5.2M |
| Aug 1, 2024 | -$1.24 | -$1.16 | Beat 6.45% | $11.1M |
| Feb 28, 2024 | -$1.54 | -$1.53 | Beat 0.65% | $6.7M |
| Aug 1, 2023 | $2.97 | -$1.44 | Miss -148.48% | — |
| Feb 27, 2023 | -$0.89 | $0.15 | Beat 116.85% | $102.7M |
| Nov 2, 2022 | -$1.11 | -$1.02 | Beat 8.11% | $1.4M |
| May 2, 2022 | -$0.67 | -$1.00 | Miss -49.25% | $1.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 1, 2027